L&C Bio Co

L&C Bio Co OCF/Debt

The Operating Cash Flow to Debt Ratio of L&C Bio Co (290650.KQ) as of Oct 17, 2026 is 312.55 %. In the previous year, Operating Cash Flow to Debt Ratio was -6.91 % — a change of -4,620.44% (higher).

OCF/Debt

312.55 %

YoY

-4,620.44%

Last updated:

Operating Cash Flow to Debt Ratio of L&C Bio Co is 2025 312.55 % . Operating Cash Flow to Debt Ratio of L&C Bio Co was 2024 -6.91 % . It decreases by -4,620.44% higher compared to the previous year.

The L&C Bio Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
384.58 KRW
Jan 1, 2019
359.07 KRW
Jan 1, 2020
49.35 KRW
Jan 1, 2021
159.66 KRW
Jan 1, 2022
-7.41 KRW
Jan 1, 2023
-14.77 KRW
Jan 1, 2024
-6.91 KRW
Jan 1, 2025
312.55 KRW
The L&C Bio Co OCF/Debt history
YEAROCF/DebtYoY
312.55 %-4,620.44%
-6.91 %-53.19%
-14.77 %+99.23%
-7.41 %-104.64%
159.66 %+223.52%
49.35 %-86.26%
359.07 %-6.63%
384.58 %-53.36%
824.65 %-15,805.14%
-5.25 %-87.59%
-42.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

L&C Bio Co Stock analysis

What does L&C Bio Co do? L&C Bio Co Ltd is a South Korean biotechnology company based in Seongnam, Gyeonggi-Do. The company went public on November 1, 2018, as indicated by its IPO date. It operates within the healthcare sector, specifically in the biotechnology industry. L&C Bio Co Ltd focuses on the development and commercialization of soft tissue allografts and medical devices. The company manufactures and sells human tissue transplant materials designed for tissue repair and filler applications. Additionally, it produces human tissue-based medical devices and cosmeceuticals. Its products are utilized across various medical fields, including vascular surgery, plastic surgery, and general surgery. The company's website is http://www.lncbio.co.kr/. L&C Bio Co Ltd is listed on the Korean stock market with the ticker symbol 290650.KQ and ISIN code KR7290650001. The company's primary business activities revolve around the production and distribution of tissue-based medical solutions, targeting both clinical and cosmetic applications. No additional details regarding founding year, key personnel, acquisitions, or specific product names beyond those mentioned are provided in the available information. L&C Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about L&C Bio Co stock

Operating Cash Flow to Debt Ratio of L&C Bio Co is 312.55 % in 2025.

Operating Cash Flow to Debt Ratio of L&C Bio Co changed from -6.91 % to 312.55 %, representing a -4,620.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio L&C Bio Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's L&C Bio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — L&C Bio Co

All Key Metrics — L&C Bio Co